AVDL AVADEL PHARMACEUTICALS PLC revenue, earnings and financials

For the quarter ended September 30, 2025, AVADEL PHARMACEUTICALS PLC reported revenue of $77.5M (up 54.9% from a year earlier), net income of $20.0K and diluted EPS of $0.00; over the last four quarters revenue was $249M and net income −$278K; for the fiscal year ended December 2024 revenue was $169M, up 504.8% on the year before.

AVDL annual revenue and earnings

• Fiscal year ended Dec 2024: revenue $169M, gross profit $154M, operating income −$42.4M, net income −$48.8M (margin -28.9%), EPS −$0.51
• Fiscal year ended Dec 2023: revenue $28.0M, gross profit $27.1M, operating income −$138M, net income −$160M (margin -573.2%), EPS −$2.00
• Fiscal year ended Dec 2022: revenue $0, gross profit $0, operating income −$98.6M, net income −$137M (margin n/a), EPS −$2.29
• Fiscal year ended Dec 2021: revenue $0, gross profit $0, operating income −$85.5M, net income −$77.3M (margin n/a), EPS −$1.32

AVDL quarterly revenue and earnings

• Quarter ended Sep 30, 2025: revenue $77.5M (up 54.9% year over year), net income $20.0K, EPS $0.00
• Quarter ended Jun 30, 2025: revenue $68.1M (up 64.2% year over year), net income $9.67M, EPS $0.10
• Quarter ended Mar 31, 2025: revenue $52.5M (up 93.2% year over year), net income −$4.92M, EPS −$0.05
• Quarter ended Dec 31, 2024 (from the annual report): revenue $50.4M (up 159.1% year over year), net income −$5.04M, EPS −$0.04
• Quarter ended Sep 30, 2024: revenue $50.0M (up 613.2% year over year), net income −$2.63M, EPS −$0.03
• Quarter ended Jun 30, 2024: revenue $41.5M (up 2674.3% year over year), net income −$13.8M, EPS −$0.14
• Quarter ended Mar 31, 2024: revenue $27.2M, net income −$27.3M, EPS −$0.30
• Quarter ended Dec 31, 2023 (from the annual report): revenue $19.5M, net income −$28.8M, EPS −$0.28
• Quarter ended Sep 30, 2023: revenue $7.01M, net income −$36.3M, EPS −$0.41
• Quarter ended Jun 30, 2023: revenue $1.50M, net income −$64.4M, EPS −$0.83
• Quarter ended Mar 31, 2023: revenue $0, net income −$30.8M, EPS −$0.48
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$27.5M, EPS −$0.44
• Quarter ended Sep 30, 2022: revenue $0, net income −$20.1M, EPS −$0.33
• Quarter ended Jun 30, 2022: revenue $0, net income −$63.4M, EPS −$1.07
• Quarter ended Mar 31, 2022: revenue n/a, net income −$26.4M, EPS −$0.45
• Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$22.3M, EPS −$0.38
• Quarter ended Sep 30, 2021: revenue $0, net income −$22.0M, EPS −$0.38
• Quarter ended Jun 30, 2021: revenue $0, net income −$19.6M, EPS −$0.33
• Quarter ended Mar 31, 2021: revenue $0, net income −$13.4M, EPS −$0.23

AVDL cash flow, buybacks and dividends

• Fiscal year ended Dec 2024: operating cash flow −$46.9M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$129M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$70.3M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$77.3M, share buybacks n/a

AVDL balance sheet

• Sep 30, 2025: cash $79.8M, total assets $199M, total liabilities $101M, shareholders' equity $98.2M
• Jun 30, 2025: cash $63.4M, total assets $187M, total liabilities $96.4M, shareholders' equity $90.7M
• Mar 31, 2025: cash $56.4M, total assets $168M, total liabilities $93.9M, shareholders' equity $74.1M
• Dec 31, 2024: cash $51.4M, total assets $164M, total liabilities $90.4M, shareholders' equity $73.8M
• Sep 30, 2024: cash $28.6M, total assets $158M, total liabilities $83.6M, shareholders' equity $74.7M
• Jun 30, 2024: cash $28.8M, total assets $158M, total liabilities $87.2M, shareholders' equity $70.3M
• Mar 31, 2024: cash $35.8M, total assets $168M, total liabilities $89.5M, shareholders' equity $78.4M
• Dec 31, 2023: cash $31.2M, total assets $165M, total liabilities $77.0M, shareholders' equity $87.7M

What is AVDL's revenue?

AVADEL PHARMACEUTICALS PLC reported $249M of revenue over its last four quarters, through September 30, 2025.

Is AVDL profitable?

No. AVADEL PHARMACEUTICALS PLC lost $278K over the last four quarters.

What is AVDL's EPS?

Diluted earnings per share over the last four quarters were $0.01; $0.00 in the latest quarter.

AVDL ownership and insider trades · All stocks